Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.69 |
| ▸ | HTR6 | P50406 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GOT1 | P17174 | 8/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5698349 | 0.98 | ADRB1 (0.67) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL20581870 | 0.84 | ADRB1 (0.75) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL8861994 | 0.83 | ADRB1 (0.73) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL30160211 | 0.83 | ADRB1 (0.73) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL1779463 | 0.83 | DRD2 (0.57) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL23102103 | 0.83 | DRD2 (0.68) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL23102113 | 0.83 | ADRB1 (0.63) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL1105118 | 0.83 | ADRB1 (0.63) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL27608171 | 0.81 | GOT1 (0.63) | ADRB1HTR6DRD2DRD4DRD3 | |
| SCHEMBL1012802 | 0.81 | ADRB1 (1.00) | ADRB1HTR6DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7220765-B2 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (SCRAS) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1335722-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1326830-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002041889-A2 | INDOLSULFONYL COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
| US-6255306-B1 | PSYCHOLOGICAL DISORDERS | MACOR JOHN E (US) | 2001-07-03 | — | — | US | disclosed |
| EP-0773942-A1 | 4-INDOLE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | PFIZER INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003400-A1 | 4-INDOLE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS | PFIZER INC. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | TYMP, PIK3CA, PDPK1 | ADRB1 2624/4885HTR6 2027/4885DRD2 3303/4885 |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SLC18A2, CNR2, TPH2 | ADRB1 346/4885HTR6 22/4885DRD2 98/4885 |
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | ADRB1 72/4885HTR6 1/4885DRD2 51/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | ADRB1 3487/4885HTR6 1881/4885DRD2 1625/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | ADRB1 80/4885HTR6 1/4885DRD2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.